Eisai Inc.
531
11
35
398
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 40/100
14.9%
79 terminated/withdrawn out of 531 trials
83.4%
-3.1% vs industry average
26%
138 trials in Phase 3/4
65%
258 of 398 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (531)
A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)
Role: collaborator
Real-World Lenvatinib Sequencing in Unresectable Hepatocellular Carcinoma (uHCC)
Role: lead
How Well and Safely Does Lemborexant Work for People Who Wake up at Night to Urinate (LENS)
Role: collaborator
A Retrospective Database Study for the Development and Validation of Algorithms for Intracerebral Hemorrhage and Seizures in Alzheimer's Disease
Role: lead
A Postmarketing Study of Lecanemab for the Treatment of Participants With Alzheimer's Disease
Role: lead
Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)
Role: collaborator
Eribulin in Angiosarcoma and Epithelioid Hemangioendothelioma (EHE)
Role: collaborator
A Study of H3B-6545 in Combination With Palbociclib in Women With Advanced or Metastatic Estrogen Receptor-Positive Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast Cancer
Role: lead
Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014).
Role: collaborator
A Study to Determine the Metabolism and Excretion of [14C]E2086 in Healthy Male Participants
Role: lead
A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, vs Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)-China Extension Study
Role: collaborator
A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2511 in Participants With Early Alzheimer's Disease (AD)
Role: lead
A Study to Assess Potential Drug-Drug Interactions of E2086 in Healthy Participants
Role: lead
Lenvatinib Plus Pembrolizumab In Patients With Immune Checkpoint Inhibitor Naïve Metastatic Uveal Melanoma
Role: collaborator
A Study of Oral E1018 in Healthy Adult Participants
Role: lead
EPOCH: Eribulin and Pembrolizumab in Ovarian/Uterine Carcinosarcoma
Role: collaborator
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol DIAN-TU-001
Role: collaborator
DIAN-TU Amyloid Removal Trial (ART) in Dominantly Inherited Alzheimer's Disease
Role: collaborator
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU)
Role: collaborator
DORA and LP in Alzheimer's Disease Biomarkers
Role: collaborator